Epigenetic aspects on therapy development for gastroenteropancreatic neuroendocrine tumors

Neuroendocrinology

Volumn 97, Issue 1, 2013, Pages 19-25

  Larsson, Catharina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

DNA methyltransferase inhibitor; Histone deacetylase inhibitor; IGF2; Menin

Indexed keywords

ANTINEOPLASTIC AGENT; DNA METHYLTRANSFERASE; HISTONE H3; HISTONE H3 LYSINE 4; METHIONINE; SOMATOMEDIN B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; DEACETYLATION; ENZYME INHIBITION; EPIGENETICS; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GENE ACTIVATION; GENE INACTIVATION; GENE LOCUS; GENE LOSS; GENOME IMPRINTING; HISTONE DEACETYLATION; HISTONE METHYLATION; HUMAN; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; GASTROINTESTINAL NEOPLASMS; GENETIC EPIGENESIS; GENETICS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

ANIMALS; EPIGENESIS, GENETIC; GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

EID: 84874106239     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000336087     Document Type: Article

References (59)

1. Monk D, Sanches R, Arnaud P, Apostolidou S, Hills FA, Abu-Amero S, Murrell A, Friess H, Reik W, Stanier P Constância M, Moore GE: Imprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and human. Hum Mol Genet 2006; 15: 1259-1269.
2. Onyango P, Feinberg AP: A nucleolar protein, H19 opposite tumor suppressor ( HOTS ) , is a tumor growth inhibitor encoded by a human imprinted H19 antisense transcript. Proc Natl Acad Sci USA 2011; 108: 16759-16764.
3. Chao W, D'Amore PA: IGF2: Epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 2008; 19: 111-120.
4. DeChiara TM, Robertson EJ, Efstratiadis A: Parental imprinting of the mouse insulinlike growth factor II gene. Cell 1991; 64: 849-859.
5. Ohlsson R, Nyström, A, Pfeifer-Ohlsson S, Töhönen V, Hedborg F, Schofield P, Flam F. Ekström TJ: IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. Nat Genet 1993; 4: 94-97.
6. Bell AC, Felsenfeld G: Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 2000; 405: 482-485.
7. Hanahan D: Heritable formation of pancreatic cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985; 315: 115-122.
8. Christofori G, Naik P, Hanahan D: A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 1994; 369: 414-418.
9. Christofori G, Naik P, Hanahan D: Deregulation of both imprinted and expressed alleles of the insulin-like growth factor 2 gene during cell tumorigenesis. Nat Genet 1995; 10: 196-201.
10. Bertolino P, Tong W, Herrera PL, Casse H, Zhang CX, Wang Z: Pancreatic cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. Cancer Res 2003; 63: 4836-4841.
11. Fontanière S, Tost J, Wierinckx A, Lachuer J, Lu J, Hussein N, Busato F, Gut I, Wang ZQ, Zhang CX: Gene expression profiling in insulinomas of Men1 cell mutant mice reveals early genetic and epigenetic events involved in pancreatic cell tumorigenesis. Endocr Relat Cancer 2006; 13: 1223-1236.
12. Höög A, Grimelius L, Falkmer S, Sara VR: A high-molecular IGF-2 immunoreactive peptide (pro-IGF-2?) in the insulin cells of the islets of Langerhans in pancreas of man and rat. Regul Peptides 1993; 47: 275-283.
13. Maake C, Reinecke M: Immunohistochemical localization of insulin-like growth factor 1 and 2 in the endocrine pancreas of rat, dog, and man, and their coexistence with classical islet hormones. Cell Tissue Res 1993; 273: 249-259.
14. Höög A, Kjellman M, Nordqvist AC, Höög CM, Juhlin C, Falkmer S, Schalling M, Grimelius L: Insulin-like growth factor-II in endocrine pancreatic tumours. Immunohistochemical, biochemical and in situ hybridization findings. APMIS 2001; 109: 127-140.
15. Dejeux E, Olaso R, Dousset B, Audebourg A, Gut IG, Terris B, Tost J: Hypermethylation of the IGF2 differentially methylated region 2 is a specific event in insulinomas leading to loss-of-imprinting and overexpression. Endocr Relat Cancer 2009; 16: 939-952.
16. Soon PS, Tacon LJ, Gill AJ, Bambachl CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG, Sidhu SB: miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res 2009; 15: 7684-7692.
17. Özata DM, Caramuta S, Velázquez-Fernández D, Akçakaya P, Xie H, Höög A, Zedenius J, Bäckdahl M, Larsson C, Lui W-O: The role of miRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 2011; 18: 643-655.
18. Pravtcheva DD, Wise TL: Metastasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice. J Exp Zool 1998; 281: 43-57.
19. Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, Fornari F, Zanesi N, Alder H, D'Elia G, Gramantieri L, Bolondi L, Lanza G, Querzoli P, Angioni A, Croce CM, Negrini M: Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res 2010; 70: 3140-3149.
20. Kanedal A, Wang CJ, Cheong R, Timp W, Onyango P, Wen B, Iacobuzio-Donahue CA, Ohlsson R, Andraos R, Pearson MA, Sharov AA, Longo DL, Ko MS, Levchenko A, Feinberg AP: Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci USA 2007; 104: 20926-20931.
21. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ: Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 1997; 276: 404-407.
22. European Consortium on MEN1: Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 1997; 6: 1177-1183.
23. Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA, Kay GF, Hayward NK, Hess JL, Meyerson M: Menin associates with a trithorax family histone methyltransferase complex and with the Hoxc8 locus. Mol Cell 2003; 13: 587-597.
24. Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, Kitabayashi I, Herr W, Cleary ML: Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 2004; 24: 5639-5649.
25. Dreijerink KM, Lips CJ, Timmers HT: Multiple endocrine neoplasia type 1: a chromatin writer's block. J Intern Med 2009; 266: 53-59.
26. Wu X, Hua X: Menin, menin, histone H3 methyltransferases, and regulation of cell proliferation: current knowledge and perspective. Curr Mol Med 2008; 8: 805-815.
27. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-5671.
28. Lemos MC, Thakker RV: Multiple endocrine neoplasia type 1 (MEN1): analysis of 1,336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008; 29: 22-32.
29. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjold M: Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332: 85-87.
30. Zhuang Z, Vortmeyer AO, Pack S, Huang S, Pham TA, Wang C, Park WS, Agarwal SK, Debelenko LV, Kester M, Guru SC, Manickam P, Olufemi SE, Yu F, Heppner C, Crabtree JS, Skarulis MC, Venzon DJ, Emmert-Buck MR, Spiegel AM, Chandrasekharappa SC, Collins FS, Burns AL, Marx SJ, Lubensky IA: Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997; 57: 4682-4686.
31. Shan L, Nakamura Y, Nakamura M, Yokoi T, Tsujimoto M, Arima R, Kameya T, Kakudo K: Somatic mutations of multiple endocrine neoplasia type 1 gene in the sporadic endocrine tumors. Lab Invest 1998; 78: 471-475.
32. Hessman O, Lindberg D, Skogseid B, Carling T, Hellman P, Rastad J, Akerstrom G, Westin G: Mutation of the multiple endocrine neoplasia type 1 gene in nonfamilial, malignant tumors of the endocrine pancreas. Cancer Res 1998; 58: 377-379.
33. Wang EH, Ebrahimi SA, Wu AY, Kashefi C, Passaro E Jr, Sawicki MP: Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res 1998; 58: 4417-4420.
34. Corbo V, Dalai I, Scardoni M, Barbi S, Beghelli S, Bersani S, Albarello L, Doglioni C, Schott C, Capelli P, Chilosi M, Boninsegna L, Becker KF, Falconi M, Scarpa A: MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer 2010; 17: 771-783.
35. Kim H, Lee JE, Cho EJ, Liu JO, Youn HD: Menin, a tumor suppressor, represses JunDmediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res 2003; 63: 6135-6139.
36. Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, McLean GW, Xiong Y, Meyerson M, Kim SK: Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci USA 2005; 102: 14659-14664.
37. Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5: 37-50.
38. Baradari V, Huether A, Höpfner M, Schuppan D, Scherübl H: Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer 2006; 13: 1237-1250.
39. Greenblatt DY, Cayo MA, Adler JT, Ning L, Haymart MR, Kunnimalaiyaan M, Chen H: Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Ann Surg 2008; 247: 1036-4100.
40. Alexander VM, Roy M, Steffens KA, Kunnimalaiyaan M, Chen H: Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids. Int J Clin Exp Med 2010; 3: 95-102.
41. Ellis LM, Samuel S, Sceusi E: Varying opinions on the authenticity of a human midgut carcinoid cell line-letter. Clin Cancer Res 2010; 16: 5365-5366.
42. Siddique Z-L, Drozdov I, Floch J, Gustafsson BI, Stunes K, Pfragner R, Mark Kidd M, Irvin M, Modlin IM: KRJ-I and BON Cell lines: defining an appropriate enterochromaffin cell neuroendocrine tumor model. Neuroendocrinology 2009; 89: 458-470.
43. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC, Pazdur R; FDA: Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005; 11: 3604-3608.
44. Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89-92.
45. Choi IS, Estecio MR, Nagano Y, Kim do H, White JA, Yao JC, Issa JP, Rashid A: Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod Pathol 2007; 20: 802-810.
46. Serrano J, Goebel SU, Peghini PL, Lubensky IA, Gibril F, Jensen RT: Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 2000; 85: 4146-4156.
47. Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, Rashid A: CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 2003; 22: 924-934.
48. Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, Boehm BO, Pfeifer GP, Hoang-Vu C: Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003; 22: 3806-3812.
49. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, Cameron JL, Hruban RH, Maitra A, Yeo CJ: Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 2003; 238: 423-431.
50. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Cameron JL, Hruban RH, Maitra A, Yeo CJ: Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms. Surgery 2003; 134: 902-908.
51. Liu L, Broaddus RR, Yao JC, Xie SS, White JA, Wu T-T, Hamilton SR, Rashid A: Epigenetic alterations in neuroendocrine tumors: methylation of RAS association domain family 1, isoform A and p16 genes are associated with metastasis. Mod Pathol 2005; 18: 1632-1640.
52. Zhang H-Y, Rumilla KM, Jin L, Nakamura N, Stilling GA, Ruebel KH, Hobday TJ, Erlichman C, Erickson LA, Lloyd RV: Association of DNA methylation and epigenetic inactivation of RASSF1A and catenin with metastasis in small bowel carcinoid tumors. Endocrine 2006; 30: 299-306.
53. Arnold CN, Sosnowski A, Schmitt-Gräff A, Arnold R, Blum HE: Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system. Int J Cancer 2007; 120: 2157-2164.
54. Lindberg D, Akerström G, Westin G: Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours. Clin Endocrinol (Oxf) 2008; 68: 271-277.
55. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G: Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998; 95: 11891-11896.
56. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, Ji H, Potash JB, Sabunciyan S, Feinberg AP: The human colon cancer methylome shows similar hypoand hypermethylation at conserved tissuespecific CpG island shores. Nat Genet 2009; 41: 178-186.
57. Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M Hsiao EC, Schuebel KE, Borges MW, Jin N, Collins BJ, Nelkin BD, Chen H, Ball DW: Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab 2005; 90: 4350-4356.
58. Stockhausen MT, Sjolund J, Manetopoulos C Axelson H: Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br J Cancer 2005; 92: 751-759.
59. Raffoux E, Chaibi P, Dombret H, Degos L: Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005; 90: 986-988.